10.1007/s40097-021-00399-5

Milk protein-based nanodelivery systems for the cancer treatment

Show Details XML
  • Nadia Tavakoli1,
  • Adeleh Divsalar*1,
  • Thomas Haertlé2,
  • Lindsay Sawyer3,
  • Ali A. Saboury4,
  • Vladimir Muronetz5,
  1. Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, IR
  2. Institute of Biochemistry and Biophysics, University of Tehran, Tehran, IR Institut National de la Recherche Agronomique et Environmentale, BIA UR 1268, Nantes, FR
  3. Institute of Quantitative Biology, Biochemistry and Biotechnology, The University of Edinburgh, Edinburgh, EH9 3JR, GB
  4. Institute of Biochemistry and Biophysics, University of Tehran, Tehran, IR
  5. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, 119234, RU

Published in Issue 05-04-2021

How to Cite

Tavakoli, N., Divsalar, A., Haertlé, T., Sawyer, L., Saboury, A. A., & Muronetz, V. (2021). Milk protein-based nanodelivery systems for the cancer treatment. Journal of Nanostructure in Chemistry, 11(4 (December 2021). https://doi.org/10.1007/s40097-021-00399-5
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Abstract The numerous advantages that nanotechnology can bring to the design of pharmaceutical delivery systems are perhaps nowhere better illustrated than in the area of cancer treatment. These nanostructures not only can improve the anti-proliferative properties of the drugs but also ameliorate the side effects by providing site-specific drug delivery. Furthermore, food-based proteins, due to their biocompatibility and biodegradability, provide a ready-made ingredient as a carrier for various chemotherapeutic agents. The most popular proteins in this field are milk proteins including β-lactoglobulin (β-LG), lactoferrin (LF), and the caseins (CN), all of which have desirable properties to make them ideal for this purpose. Grafting these two approaches, different milk protein-based nanodrugs have been synthesized that show promising potential in providing more targeted delivery of drugs thereby reducing the cytotoxic effects of chemotherapy. In some cases, being encapsulated in these proteins (in nanoscale), the chemotherapeutic agents can be consumed orally while enhancing site-specific delivery. This article reviews various nanodrug delivery systems containing milk proteins, which are designed for cancer treatment. Moreover, their physical and their anti-proliferative characteristics are briefly described. Graphic abstract

Keywords

  • Milk proteins,
  • Casein,
  • Cancer,
  • Nanoparticles,
  • Drug delivery

References

  1. Livney (2010) Milk proteins as vehicles for bioactives 15(1) (pp. 73-83) https://doi.org/10.1016/j.cocis.2009.11.002
  2. Zimecki and Kruzel (2007) Milk-derived proteins and peptides of potential therapeutic and nutritive value 6(2) (pp. 89-106)
  3. Jenness (1974) Biosynthesis and composition of milk 63(1) (pp. 109-118) https://doi.org/10.1111/1523-1747.ep12678111
  4. Dalgleish and Corredig (2012) The structure of the casein micelle of milk and its changes during processing (pp. 449-467) https://doi.org/10.1146/annurev-food-022811-101214
  5. Dickinson (1989) Surface and emulsifying properties of caseins 56(3) (pp. 471-477) https://doi.org/10.1017/S0022029900028958
  6. Miller et al. (1990) Casein: a milk protein with diverse biologic consequences 195(2) (pp. 143-159) https://doi.org/10.3181/00379727-195-43129
  7. Glantz et al. (2010) Importance of casein micelle size and milk composition for milk gelation 93(4) (pp. 1444-1451) https://doi.org/10.3168/jds.2009-2856
  8. Vasbinder et al. (2003) Gelation mechanism of milk as influenced by temperature and pH; studied by the use of transglutaminase cross-linked casein micelles 86(5) (pp. 1556-1563) https://doi.org/10.3168/jds.S0022-0302(03)73741-2
  9. Hoffman and Falvo (2004) Protein—which is best? 3(3) (pp. 118-130)
  10. Madureira et al. (2007) Bovine whey proteins—overview on their main biological properties 40(10) (pp. 1197-1211) https://doi.org/10.1016/j.foodres.2007.07.005
  11. Smithers (2008) Whey and whey proteins—from ‘gutter-to-gold’ 18(7) (pp. 695-704) https://doi.org/10.1016/j.idairyj.2008.03.008
  12. Davoodi et al. (2016) Health-related aspects of milk proteins 15(3) (pp. 573-591)
  13. Wu et al. (1996) Disulfide determinants of calcium-induced packing in alpha-lactalbumin 35(3) (pp. 859-863) https://doi.org/10.1021/bi951408p
  14. Layman et al. (2018) Applications for alpha-lactalbumin in human nutrition 76(6) (pp. 444-460) https://doi.org/10.1093/nutrit/nuy004
  15. Kamau et al. (2010) Alpha-lactalbumin: its production technologies and bioactive peptides 9(2) (pp. 197-212) https://doi.org/10.1111/j.1541-4337.2009.00100.x
  16. Shafaei et al. (2017) beta-Lactoglobulin: an efficient nanocarrier for advanced delivery systems 13(5) (pp. 1685-1692) https://doi.org/10.1016/j.nano.2017.03.007
  17. Wu et al. (1999) beta-Lactoglobulin binds palmitate within its central cavity 274(1) (pp. 170-174) https://doi.org/10.1074/jbc.274.1.170
  18. Zimet and Livney (2009) Beta-lactoglobulin and its nanocomplexes with pectin as vehicles for ω-3 polyunsaturated fatty acids (pp. 1120-1126) https://doi.org/10.1016/j.foodhyd.2008.10.008
  19. Dodin et al. (1990) Binding of ellipticine to β-lactoglobulin 193(3) (pp. 697-700) https://doi.org/10.1111/j.1432-1033.1990.tb19389.x
  20. Humphrey et al. (1996) VMD: visual molecular dynamics 14(1) (pp. 33-38) https://doi.org/10.1016/0263-7855(96)00018-5
  21. Loch et al. (2011) Two modes of fatty acid binding to bovine beta-lactoglobulin-crystallographic and spectroscopic studies 24(2) (pp. 341-349) https://doi.org/10.1002/jmr.1084
  22. Valenti et al. (2004) Lactoferrin functions: current status and perspectives 38(6 Suppl) (pp. S127-129) https://doi.org/10.1097/01.mcg.0000128941.46881.33
  23. Chierici (2001) Antimicrobial actions of lactoferrin (pp. 247-269) https://doi.org/10.1007/978-1-4615-0661-4_12
  24. Zhang et al. (2014) Anticancer effects of lactoferrin: underlying mechanisms and future trends in cancer therapy 72(12) (pp. 763-773) https://doi.org/10.1111/nure.12155
  25. Brock (2002) The physiology of lactoferrin 80(1) (pp. 1-6) https://doi.org/10.1139/o01-212
  26. Lim et al. (2015) Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes 11(6) (pp. 1445-1454) https://doi.org/10.1016/j.nano.2015.04.006
  27. Golla et al. (2013) A target-specific oral formulation of doxorubicin–protein nanoparticles: efficacy and safety in hepatocellular cancer (pp. 644-652) https://doi.org/10.7150/jca.7093
  28. Moore et al. (1997) Three-dimensional structure of diferric bovine lactoferrin at 2.8 A resolution 274(2) (pp. 222-236) https://doi.org/10.1006/jmbi.1997.1386
  29. Organization, W.H.: Cancer. (2019).
  30. https://www.who.int/cancer/resources/keyfacts/en/
  31. . Accessed 1 Dec 2019
  32. Arruebo et al. (2011) Assessment of the evolution of cancer treatment therapies 3(3) (pp. 3279-3330) https://doi.org/10.3390/cancers3033279
  33. Nurgali et al. (2018) Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? (pp. 245-245) https://doi.org/10.3389/fphar.2018.00245
  34. Chakraborty and Rahman (2012) The difficulties in cancer treatment https://doi.org/10.3332/ecancer.2012.ed16
  35. Housman et al. (2014) Drug resistance in cancer: an overview 6(3) (pp. 1769-1792) https://doi.org/10.3390/cancers6031769
  36. Elshimali et al. (2018) Optimization of cancer treatment through overcoming drug resistance 1(2) https://doi.org/10.31021/jcro.20181107
  37. Schirrmacher (2019) From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (review) 54(2) (pp. 407-419) https://doi.org/10.3892/ijo.2018.4661
  38. Zhang et al. (2018) Natural product interventions for chemotherapy and radiotherapy-induced side effects (pp. 1253-1253) https://doi.org/10.3389/fphar.2018.01253
  39. Jansman et al. (2001) Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer 24(5) (pp. 353-367) https://doi.org/10.2165/00002018-200124050-00002
  40. Wang et al. (2019) Drug resistance and combating drug resistance in cancer https://doi.org/10.20517/cdr.2019.10
  41. Tran et al. (2017) Cancer nanomedicine: a review of recent success in drug delivery 6(1) (pp. 44-44) https://doi.org/10.1186/s40169-017-0175-0
  42. Kumar and Kaur (2020) Sprayed in-situ synthesis of polyvinyl alcohol/chitosan loaded silver nanocomposite hydrogel for improved antibacterial effects (pp. 950-964) https://doi.org/10.1016/j.ijbiomac.2019.09.186
  43. Kumar et al. (2020) A rationalized and innovative perspective of nanotechnology and nanobiotechnology in chronic wound management https://doi.org/10.1016/j.jddst.2020.101930
  44. Kumar et al. (2014) Enhanced intestinal permeability of Tinospora cordifolia extract through nanoemulsion formulation: in-vitro and ex-vivo studies (pp. 1-10)
  45. Chadha et al. (2020) Inulin as a delivery vehicle for targeting colon-specific cancer 17(8) (pp. 651-674) https://doi.org/10.2174/1567201817666200527133719
  46. Arun et al. (2020) Synthesis of nanostructured lipid carriers loaded chitosan/carbopol hybrid nanocomposite gel for oral delivery of artemether and curcumin 8(5) (pp. 418-432) https://doi.org/10.2174/2211738508666200907110444
  47. Calzoni et al. (2019) Biocompatible polymer nanoparticles for drug delivery applications in cancer and neurodegenerative disorder therapies 10(1) https://doi.org/10.3390/jfb10010004
  48. Jadia et al. (2016) Nanoparticles for effective combination therapy of cancer https://doi.org/10.33140/IJNN/01/01/00003
  49. Elzoghby et al. (2012) Protein-based nanocarriers as promising drug and gene delivery systems 161(1) (pp. 38-49) https://doi.org/10.1016/j.jconrel.2012.04.036
  50. Chen et al. (2006) Food protein-based materials as nutraceutical delivery systems 17(5) (pp. 272-283) https://doi.org/10.1016/j.tifs.2005.12.011
  51. Shapira et al. (2010) Beta-casein nanovehicles for oral delivery of chemotherapeutic drugs 6(1) (pp. 119-126) https://doi.org/10.1016/j.nano.2009.06.006
  52. Bijari et al. (2019) β-Lactoglobulin-irinotecan inclusion complex as a new targeted nanocarrier for colorectal cancer cells 14(3) (pp. 216-227) https://doi.org/10.4103/1735-5362.258488
  53. Farokhzad and Langer (2009) Impact of nanotechnology on drug delivery 3(1) (pp. 16-20) https://doi.org/10.1021/nn900002m
  54. Burgess et al. (2010) On firm ground: IP protection of therapeutic nanoparticles 28(12) (pp. 1267-1270) https://doi.org/10.1038/nbt.1725
  55. Choe et al. (1998) Enhancement of cationic liposome-mediated transfection by lactoferrin 12(7) (pp. 577-581) https://doi.org/10.1023/A:1008836110996
  56. Salatin et al. (2017) Development of a nanoprecipitation method for the entrapment of a very water soluble drug into Eudragit RL nanoparticles 12(1) (pp. 1-14) https://doi.org/10.4103/1735-5362.199041
  57. Yadav and Sawant (2010) Modified nanoprecipitation method for preparation of cytarabine-loaded PLGA nanoparticles 11(3) (pp. 1456-1465) https://doi.org/10.1208/s12249-010-9519-4
  58. Abdelmoneem et al. (2018) Decorating protein nanospheres with lactoferrin enhances oral COX-2 inhibitor/herbal therapy of hepatocellular carcinoma 13(19) (pp. 2377-2395) https://doi.org/10.2217/nnm-2018-0134
  59. Kanwar et al. (2012) Nano-lactoferrin in diagnostic, imaging and targeted delivery for cancer and infectious diseases (pp. 31-42) https://doi.org/10.4172/1948-5956.1000107
  60. Pang et al. (2010) Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats 7(6) (pp. 1995-2005) https://doi.org/10.1021/mp100277h
  61. Chen et al. (2010) Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery 40(2) (pp. 94-102) https://doi.org/10.1016/j.ejps.2010.03.007
  62. Chen et al. (2011) Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas 44(1–2) (pp. 164-173) https://doi.org/10.1016/j.ejps.2011.07.007
  63. Kanwar et al. (2012) Novel alginate-enclosed chitosan-calcium phosphate-loaded iron-saturated bovine lactoferrin nanocarriers for oral delivery in colon cancer therapy 7(10) (pp. 1521-1550) https://doi.org/10.2217/nnm.12.29
  64. Mahidhara et al. (2015) Oral administration of iron-saturated bovine lactoferrin-loaded ceramic nanocapsules for breast cancer therapy and influence on iron and calcium metabolism (pp. 4081-4098) https://doi.org/10.2147/IJN.S75877
  65. Kanwar et al. (2015) Fe-bLf nanoformulation targets survivin to kill colon cancer stem cells and maintains absorption of iron, calcium and zinc 10(1) (pp. 35-55) https://doi.org/10.2217/nnm.14.132
  66. Abdelmoneem et al. (2019) Dual-targeted lactoferrin shell-oily core nanocapsules for synergistic targeted/herbal therapy of hepatocellular carcinoma 11(30) (pp. 26731-26744) https://doi.org/10.1021/acsami.9b10164
  67. Sabra et al. (2018) Self-assembled amphiphilic zein-lactoferrin micelles for tumor targeted co-delivery of rapamycin and wogonin to breast cancer (pp. 156-169) https://doi.org/10.1016/j.ejpb.2018.04.023
  68. Ko and Gunasekaran (2006) Preparation of sub-100-nm beta-lactoglobulin (BLG) nanoparticles 23(8) (pp. 887-898) https://doi.org/10.1080/02652040601035143
  69. Sahoo et al. (2008) Investigating the binding of curcumin derivatives to bovine serum albumin 132(2) (pp. 81-88) https://doi.org/10.1016/j.bpc.2007.10.007
  70. Barik et al. (2007) Interaction of curcumin with human serum albumin: thermodynamic properties, fluorescence energy transfer and denaturation effects 436(1) (pp. 239-243) https://doi.org/10.1016/j.cplett.2007.01.006
  71. Mohammadi et al. (2009) Interaction of curcumin and diacetylcurcumin with the lipocalin member beta-lactoglobulin 28(3–4) (pp. 117-123) https://doi.org/10.1007/s10930-009-9171-6
  72. Divsalar et al. (2013) Cytotoxic and spectroscopic studies on binding of a new synthesized bipyridine ethyl dithiocarbamate Pt(II) nitrate complex to the milk carrier protein of BLG 10(5) (pp. 951-959) https://doi.org/10.1007/s13738-013-0232-6
  73. Sneharani et al. (2010) Interaction of curcumin with beta-lactoglobulin-stability, spectroscopic analysis, and molecular modeling of the complex 58(20) (pp. 11130-11139) https://doi.org/10.1021/jf102826q
  74. Teng et al. (2014) Insight into curcumin-loaded β-lactoglobulin nanoparticles: incorporation, particle disintegration, and releasing profiles 62(35) (pp. 8837-8847) https://doi.org/10.1021/jf503199g
  75. Li et al. (2015) Absorption mechanism of whey-protein-delivered curcumin using Caco-2 cell monolayers (pp. 48-54) https://doi.org/10.1016/j.foodchem.2015.01.132
  76. Aditya et al. (2015) Fabrication of amorphous curcumin nanosuspensions using β-lactoglobulin to enhance solubility, stability, and bioavailability (pp. 114-121) https://doi.org/10.1016/j.colsurfb.2015.01.027
  77. Divsalar et al. (2007) Binding properties of a new anti-tumor component (2,2′-bipyridin octylglycinato Pd(II) nitrate) with bovine β-lactoglobulin-A and -B (pp. 173-182) https://doi.org/10.1080/07391102.2007.10507166
  78. Abazari et al. (2020) Inhibitory effects of oxali-platin as a chemotherapeutic drug on the function and structure of bovine liver catalase 38(2) (pp. 609-615) https://doi.org/10.1080/07391102.2019.1581088
  79. Mohammadgholi et al. (2020) Multi-spectroscopic studies of the interaction of new synthesized platin complex with human carrier protein of serum albumin (pp. 1-6) https://doi.org/10.1080/07391102.2020.1745690
  80. Divsalar et al. (2009) Comparative studies on the interaction between bovine beta-lacto-globulin type A and B and a new designed Pd(II) complex with anti-tumor activity at different temperatures 26(5) (pp. 587-597) https://doi.org/10.1080/07391102.2009.10507274
  81. Divsalar et al. (2007) Spectroscopic and cytotoxic studies of the novel designed palladium(II) complexes: β-lactoglobulin and K562 as the targets 40(4) (pp. 381-386) https://doi.org/10.1016/j.ijbiomac.2006.09.015
  82. Divsalar et al. (2007) Binding properties of a new anti-tumor component (2,2'-bipyridin octylglycinato Pd(II) nitrate) with bovine beta-lactoglobulin-A and -B 25(2) (pp. 173-182) https://doi.org/10.1080/07391102.2007.10507166
  83. Divsalar et al. (2009) Comparative studies on the interaction between bovine β-lacto-globulin type A and B and a new designed Pd(II) complex with anti-tumor activity at different temperatures 26(5) (pp. 587-597) https://doi.org/10.1080/07391102.2009.10507274
  84. Leilabadi-Asl et al. (2018) Probing the interaction of two chemotherapeutic drugs of oxali-palladium and 5-fluorouracil simultaneously with milk carrier protein of β-lactoglobulin (pp. 422-432) https://doi.org/10.1016/j.ijbiomac.2018.01.067
  85. Ghalandari et al. (2014) Spectroscopic and theoretical investigation of oxali–palladium interactions with β-lactoglobulin (pp. 1038-1046) https://doi.org/10.1016/j.saa.2013.09.126
  86. Ghalandari et al. (2014) The new insight into oral drug delivery system based on metal drugs in colon cancer therapy through beta-lactoglobulin/oxali-palladium nanocapsules (pp. 255-265) https://doi.org/10.1016/j.jphotobiol.2014.08.003
  87. Divsalar et al. (2010) Design, synthesis, and biological evaluation of a new palladium(II) complex: β-lactoglobulin and K562 as targets 114(10) (pp. 3639-3647) https://doi.org/10.1021/jp909143b
  88. Divsalar et al. (2013) Thermal study of a newly synthesized Cu(II) complex binding to bovine https://doi.org/10.1155/2013/453056
  89. Zheng et al. (2016) Selenium modification of beta-lactoglobulin (beta-Lg) and its biological activity (pp. 246-251) https://doi.org/10.1016/j.foodchem.2016.01.016
  90. Zhao et al. (2018) Apoptosis and autophagy induction of seleno-β-lactoglobulin (Se-β-Lg) on hepatocellular carcinoma cells lines (pp. 412-423) https://doi.org/10.1016/j.jff.2018.09.011
  91. Sun et al. (2017) Antitumor and immunoregulatory activities of seleno-β-lactoglobulin on S180 tumor-bearing mice https://doi.org/10.3390/molecules23010046
  92. Zheng et al. (2018) Selenious-β-lactoglobulin induces the apoptosis of human lung cancer A549 cells via an intrinsic mitochondrial pathway (pp. 1551-1563) https://doi.org/10.1007/s10616-018-0248-y
  93. Yu et al. (2018) Antitumor effects of seleno-beta-lactoglobulin (Se-beta-Lg) against human gastric cancer MGC-803 cells (pp. 109-115) https://doi.org/10.1016/j.ejphar.2018.05.042
  94. Zhang et al. (2018) Development, physicochemical characterization and cytotoxicity of selenium nanoparticles stabilized by beta-lactoglobulin 107(Pt B) (pp. 1406-1413) https://doi.org/10.1016/j.ijbiomac.2017.09.117
  95. Brauckmann et al. (2013) The interaction of platinum-based drugs with native biologically relevant proteins 405(6) (pp. 1855-1864) https://doi.org/10.1007/s00216-012-6410-z
  96. Ghalandari et al. (2015) Probing of the interaction between beta-lactoglobulin and the anticancer drug oxaliplatin 175(2) (pp. 974-987) https://doi.org/10.1007/s12010-014-1341-0
  97. Brauckmann et al. (2013) Influence of cimetidine and its metabolites on cisplatin—investigation of adduct formation by means of electrochemistry/liquid chromatography/electrospray mass spectrometry (pp. 49-57) https://doi.org/10.1016/j.chroma.2012.12.069
  98. Izadi et al. (2016) beta-Lactoglobulin-pectin nanoparticle-based oral drug delivery system for potential treatment of colon cancer 88(2) (pp. 209-216) https://doi.org/10.1111/cbdd.12748
  99. Jones et al. (2010) Thermal analysis of β-lactoglobulin complexes with pectins or carrageenan for production of stable biopolymer particles 24(2/3) (pp. 239-248) https://doi.org/10.1016/j.foodhyd.2009.10.001
  100. Bijari et al. (2017) Irinotecan binds to the internal cavity of beta-lactoglobulin: a multi-spectroscopic and computational investigation (pp. 109-115) https://doi.org/10.1016/j.jpba.2017.02.050
  101. Langer et al. (2003) Optimization of the preparation process for human serum albumin (HSA) nanoparticles 257(1–2) (pp. 169-180) https://doi.org/10.1016/s0378-5173(03)00134-0
  102. Jahanban-Esfahlan et al. (2016) A simple improved desolvation method for the rapid preparation of albumin nanoparticles (pp. 703-709) https://doi.org/10.1016/j.ijbiomac.2016.05.032
  103. Rahimi Yazdi and Corredig (2012) Heating of milk alters the binding of curcumin to casein micelles. A fluorescence spectroscopy study 132(3) (pp. 1143-1149) https://doi.org/10.1016/j.foodchem.2011.11.019
  104. Ghayour et al. (2019) Nanoencapsulation of quercetin and curcumin in casein-based delivery systems (pp. 394-403) https://doi.org/10.1016/j.foodhyd.2018.08.031
  105. Esmaili et al. (2011) Beta casein-micelle as a nano vehicle for solubility enhancement of curcumin; food industry application 44(10) (pp. 2166-2172) https://doi.org/10.1016/j.lwt.2011.05.023
  106. Priya et al. (2020) Curcumin-loaded layer-by-layer folic acid and casein coated carboxymethyl cellulose/casein nanogels for treatment of skin cancer 13(1) (pp. 694-708) https://doi.org/10.1016/j.arabjc.2017.07.010
  107. Bachar et al. (2012) Development and characterization of a novel drug nanocarrier for oral delivery, based on self-assembled beta-casein micelles 160(2) (pp. 164-171) https://doi.org/10.1016/j.jconrel.2012.01.004
  108. Knepp et al. (1993) Synthesis, properties, and intratumoral evaluation of mitoxantrone-loaded casein microspheres in Lewis lung carcinoma 45(10) (pp. 887-891) https://doi.org/10.1111/j.2042-7158.1993.tb05614.x
  109. Latha et al. (1996) Anti-tumor effect of mitoxantrone-loaded bovine casein microspheres on Ehrlich ascites carcinoma in mice 3(2) (pp. 75-79) https://doi.org/10.3109/10717549609031176
  110. Shapira et al. (2010) Beta-casein-based nanovehicles for oral delivery of chemotherapeutic drugs: drug-protein interactions and mitoxantrone loading capacity 6(4) (pp. 547-555) https://doi.org/10.1016/j.nano.2010.01.003
  111. Shapira et al. (2010) Beta-casein nanoparticles as an oral delivery system for chemotherapeutic drugs: impact of drug structure and properties on co-assembly 27(10) (pp. 2175-2186) https://doi.org/10.1007/s11095-010-0222-7
  112. Shapira et al. (2012) beta-Casein nanoparticle-based oral drug delivery system for potential treatment of gastric carcinoma: stability, target-activated release and cytotoxicity 80(2) (pp. 298-305) https://doi.org/10.1016/j.ejpb.2011.10.022
  113. Narayanan et al. (2015) Sequential release of epigallocatechin gallate and paclitaxel from PLGA-casein core/shell nanoparticles sensitizes drug-resistant breast cancer cells 11(6) (pp. 1399-1406) https://doi.org/10.1016/j.nano.2015.03.015
  114. Elzoghby et al. (2013) Micellar delivery of flutamide via milk protein nanovehicles enhances its anti-tumor efficacy in androgen-dependent prostate cancer rat model 30(10) (pp. 2654-2663) https://doi.org/10.1007/s11095-013-1091-7
  115. Elzoghby et al. (2013) Ionically-crosslinked milk protein nanoparticles as flutamide carriers for effective anticancer activity in prostate cancer-bearing rats 85(3 Pt A) (pp. 444-451) https://doi.org/10.1016/j.ejpb.2013.07.003
  116. Elzoghby et al. (2013) Novel ionically crosslinked casein nanoparticles for flutamide delivery: formulation, characterization, and in vivo pharmacokinetics (pp. 1721-1732) https://doi.org/10.2147/ijn.S40674
  117. Elgindy et al. (2014) Casein-based micelles: a novel vector for delivery of the poorly soluble anticancer drug, flutamide? 5(1) (pp. 7-9) https://doi.org/10.4155/tde.13.122
  118. Elzoghby et al. (2013) Spray-dried casein-based micelles as a vehicle for solubilization and controlled delivery of flutamide: formulation, characterization, and in vivo pharmacokinetics 84(3) (pp. 487-496) https://doi.org/10.1016/j.ejpb.2013.01.005
  119. Gandhi and Roy (2019) Doxorubicin-loaded casein nanoparticles for drug delivery: preparation, characterization and in vitro evaluation (pp. 6-12) https://doi.org/10.1016/j.ijbiomac.2018.10.005
  120. Huang et al. (2015) Layer-by-layer assembled milk protein coated magnetic nanoparticle enabled oral drug delivery with high stability in stomach and enzyme-responsive release in small intestine (pp. 105-113) https://doi.org/10.1016/j.biomaterials.2014.10.059
  121. Wang et al. (2019) Preparation and characterization of β-casein stabilized lipopeptide lyotropic liquid crystal nanoparticles for delivery of doxorubicin 15(44) (pp. 9011-9017) https://doi.org/10.1039/C9SM01931F
  122. Zhen et al. (2013) Cellular uptake, antitumor response and tumor penetration of cisplatin-loaded milk protein nanoparticles 34(4) (pp. 1372-1382) https://doi.org/10.1016/j.biomaterials.2012.10.061
  123. Huang et al. (2016) Functionalized milk-protein-coated magnetic nanoparticles for MRI-monitored targeted therapy of pancreatic cancer (pp. 3087-3099) https://doi.org/10.2147/ijn.S92722
  124. Divsalar et al. (2015) Biological evaluation of a new synthesized Pt(II) complex by cytotoxic and spectroscopic studies 71(3) (pp. 1415-1424) https://doi.org/10.1007/s12013-014-0364-z
  125. Razmi and Divsalar (2013) The effect of Β-casein nanoparticles on bioavailability and cellular uptake of platinum complex as a cancer drug 18(9) (pp. 711-722)
  126. Razmi et al. (2013) Beta-casein and its complexes with chitosan as nanovehicles for delivery of a platinum anticancer drug (pp. 362-367) https://doi.org/10.1016/j.colsurfb.2013.08.022
  127. Divsalar et al. (2014) The design and characterization of a novel beta-casein nano-vehicle loaded with platinum anticancer drug for drug delivery 14(6) (pp. 892-900) https://doi.org/10.2174/1871520614666140207123147
  128. Liang et al. (2018) Natural brain penetration enhancer-modified albumin nanoparticles for glioma targeting delivery 10(36) (pp. 30201-30213) https://doi.org/10.1021/acsami.8b11782
  129. Gao et al. (2019) Menthol-modified casein nanoparticles loading 10-hydroxycamptothecin for glioma targeting therapy 9(4) (pp. 843-857) https://doi.org/10.1016/j.apsb.2019.01.006